Adequan Equine Injectable is an FDA-approved injectable medication prescribed for the treatment of equine non-infectious degenerative joint disease (DJD), specifically in the carpal and hock joints (the equivalent of the ankle bone in humans). DJD can cause joint pain and inflammation, which can often lead to horse lameness. Lameness occurs when the horse overcompensates for the affected area, resulting in abnormal movements. Adequan can help reduce the damaging process of DJD, help reverse the loss of cartilage and encourage healthy joint function and associated lameness.
Adequan Equine Injectable (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Possible Side Effects
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.
Drug & Food Interactions
Talk to your veterinarian about any other drugs your horse is taking before starting this medication.
Studies have not been conducted to establish safety in breeding horses. Do not use in animals intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Confirmed by findings from a Dose Titration Study, the recommended dosage1 of Adequan is 500 mg every 4 days for 28 days intramuscularly (for a total of 7 injections). No, upon an initial diagnosis of Degenerative Joint Disease, treatment recommendations are to initiate 500 mg every 4 days for 28 days intramuscularly. The series may be repeated as needed upon recurrence of the clinical signs of Degenerative Joint Disease and associated lameness of the carpal and hock joints.
Store at controlled room temperatures between 68° – 77°F; excursions permitted to 59° – 86°F.